Topic: breast cancer

AstraZeneca manufacturing employee

44. Enhertu

AstraZeneca and Daiichi Sankyo hoped their antibody-drug conjugate could help a tough-to-treat group of breast cancer patients—and the FDA agreed to give it a shot in late December despite a shaky safety profile.

12. Piqray

On the same day the FDA approved gene therapy Zolgensma, the U.S. regulator also waved through breast cancer drug Piqray. It is the first drug meant specifically for HR+/HER2- breast cancer patients with a PIK3CA mutation.